STOCK TITAN

Definium Therapeutics (DFTX) director awarded RSUs and stock options in new grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Definium Therapeutics director Carol A. Vallone received equity-based compensation consisting of restricted stock units and stock options. She was granted 4,666 RSUs, each representing one common share at no purchase price, bringing her direct holdings to 21,210 common shares.

Vallone also received a stock option covering 19,188 common shares at an exercise price of $24.11 per share, expiring on June 10, 2036. Both the RSUs and the option vest in 12 equal monthly installments from the grant date, with any remaining unvested portion vesting earlier immediately before the issuer’s next annual meeting if it occurs within the first year, subject to her continued service.

Positive

  • None.

Negative

  • None.
Insider Vallone Carol A
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 19,188 $0.00 --
Grant/Award Common Shares 4,666 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 19,188 shares (Direct, null); Common Shares — 21,210 shares (Direct, null)
Footnotes (1)
  1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date. The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.
Restricted stock units granted 4,666 shares RSU grant to director on June 11, 2026
Stock options granted 19,188 shares Option grant to director on June 11, 2026
Option exercise price $24.11 per share Stock option strike price
Option expiration June 10, 2036 Stock option expiry date
Shares held after grant 21,210 shares Director’s direct common share holdings post-transaction
RSU vesting schedule 1/12 monthly Monthly vesting over 12 months from grant date
Option vesting schedule 1/12 monthly Monthly vesting over 12 months from grant date
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option financial
"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
contingent right financial
"Each RSU represents a contingent right to receive one common share of the Issuer"
vests and becomes exercisable financial
"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares"
annual meeting financial
"immediately prior to the Issuer's annual meeting following the date of grant"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Vallone Carol A

(Last)(First)(Middle)
C/O DEFINIUM THERAPEUTICS, INC.
ONE WORLD TRADE CENTER, SUITE 8500

(Street)
NEW YORK NEW YORK 10007

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Definium Therapeutics, Inc. [ DFTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares06/11/2026A4,666(1)A$021,210D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$24.1106/11/2026A19,188 (2)06/10/2036Common Shares19,188$019,188D
Explanation of Responses:
1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.
2. The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.
/s/ Mark Sullivan, Attorney-in-Fact for Carol A Vallone06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Definium Therapeutics (DFTX) grant to director Carol A. Vallone?

Definium Therapeutics granted Carol A. Vallone 4,666 restricted stock units and a stock option for 19,188 common shares. These equity awards were issued as compensation and involve no cash purchase at grant, aligning her incentives with common shareholders.

How do Carol A. Vallone’s RSUs in Definium Therapeutics (DFTX) vest?

Vallone’s 4,666 RSUs vest as to one-twelfth of the underlying shares on each monthly anniversary of the grant date. Any remaining unvested RSUs vest immediately before the next annual meeting if it falls within a year, subject to her continued service.

What are the key terms of Carol A. Vallone’s Definium Therapeutics (DFTX) stock option?

She received a stock option for 19,188 common shares at an exercise price of $24.11 per share, expiring June 10, 2036. The option vests in 12 equal monthly installments from the grant date, contingent on her continued service with the company.

How many Definium Therapeutics (DFTX) common shares does Carol A. Vallone hold after this Form 4?

Following the grant of 4,666 RSU-based common shares, Carol A. Vallone directly holds 21,210 common shares. This figure reflects her direct ownership after the reported award and helps indicate her equity stake as a company director.

Can Carol A. Vallone’s Definium Therapeutics (DFTX) RSUs vest earlier than monthly installments?

Yes. While RSUs normally vest monthly over 12 months, any unvested RSUs will fully vest immediately before the company’s next annual meeting if it occurs within one year of grant, assuming she remains in service through that vesting date.